This model sizes the market for claims processing in healthcare payers from 2007-2013. The model is segmented into government and private payers. In addition the market is broken down between BPO and in-house services.

This 130+ paged report features key figures, including graphs and charts, important tables, news, insights, the latest developments in the parallel trade market with up-to-date analysis.

This report focuses on the latest developments in pricing and reimbursement (P&R) in the seven major markets providing analysis of P&R controls in each market and identifying key trends shaping overall market evolution and implications for Pharma

The pharmaceutical industry produces increasingly complex products, with reduced time-to-market windows, and stringent domestic and international regulatory and compliance requirements. Datamonitor views PLM technology as one of the most rapidly growi

Overview of the complex Medicare Part D environment in the US, charting the program's evolution over the last 15 months since roll-out, together with the problems that it has faced, and followed by identifying possible remedies to these issues.

Datamonitor has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how pa

Analysis of the current trends in pharmaceutical portfolio management with a focus on the interaction between marketed and R&D portfolios, and creation of additional value through portfolio synergies within a given therapeutic area.

Streamlining product development processes is becoming a major priority for pharmaceutical manufacturers looking to improve their market share, and respond to growing regulatory pressure and competition. This Datamonitor model forecasts the IT opportun

Use this report to benchmark your branding strategies against those of the industry’s leaders and ensure that your company is maximizing profit by effectively building and communicating brands.

This report performs a comprehensive examination of current competitive pressures, best practices and future developments in key therapeutic areas including cardiovascular, respiratory, HIV and women’s health.

NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated

Don’t allow your product’s commercial potential to falter. Use Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch to bolster your case for larger commercial budgets and to benchmark your marketing spends in pre-clini

A new report featuring case studies of successful product launches of several key drugs. The results of 163 new product approvals and launches conducted across the US and EU are analyzed to provide up-to-date information on trends in new drug launches

An in-depth analysis of the pharmacovigilance technology market including market conditions, adoption strategies, and technology trends.

This report examines the tactical importance of price optimization throughout the product lifecycle.

Use the case studies in this report to identify best practice examples of indication expansion strategies and ensure that you can implement these into your current processes to maximize the lifecycle of your products.

This report provides a rigorous examination of the four major issues that will shape the competitive situation. The report also constructs four alternative robust scenarios that allow you to decide the likely future outlook for your company and the str

This report presents a comprehensive overview of effective portfolio management processes, with a focus on better preparing senior management, R&D and marketing executives for integrated decision-making across the organization as a whole.

This report analyzes the latest developments in DTC marketing and unveils the new channels and markets that have the potential to boost product sales, awareness and revenue.

In-depth analysis of the current growth opportunities, threats, leading players and their future prospects; it will enable you to understand the most attractive market sectors and discover what will influence competitive strategy and franchise developm

This report examines the benefits of Internet-based solutions as a way of targeting physicians and overcoming declining productivity in the sales process. eDetailing could potentially reduce detailing costs and increase amount of time physicians are p

This report provides a timely market update, examining leading products and pipeline prospects in seven key lifestyle drug sectors, and is supported by forecasts to 2008. Today`s R&D is influenced as much by commercial unmet needs as it is by clinical

This report structures and strategies to maximize ROI and boost product uptake’ provides a detailed, timely examination of sales force structures and the factors that impact sales force return on investment (ROI).

This report examines the most commonly used pharmacoeconomic methodologies with respect to both study perspective and the range of R&D costs that can be analyzed.

Thid management report examines global pricing of pharmaceutical and biotechnology products and maps out the future scenarios affecting companies.

A new management report by Reuters Business Insight, provides timely sales data on all 58 products generating sales above $1bn in 2002.

This report quantifies the patient potential in different cancer sub-markets and provides benchmarks for new cancer drug development and marketing strategies; identifying key areas of unmet need and profiling the market leading products of the future.<

This report analyses the recent performance of the OTC markets in the US, Japan, Germany, the UK and France.

This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development.